6RYBAK M,LOMAESTRO B,ROTSCHAFER JC,et al.Therapeutic monitoring of vancomycin in adult patients:a consensus review of the American Society of Health-System Pharmacists,the Infectious Diseases Society of America,and the Society of Infectious Diseases Pharmacists[J].Am J Health Syst Pharm,2009,66(1):82-92.
7TANAKA A,SUEMARU K,OTSUKA T,et al.Estimation of the initial dose setting of vancomycin therapy with use of cystatin C as a new marker of renal function[J].Ther Drug Monit,2007,29(2):261-264.
8FRYMOYER A,HERSH AL,BENET LZ,et al.Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate[J].Pediatr Infect Dis J,2009,28(5):398-402.
9HAZLEWOOD KA,BROUSE SD,PITCHER WD,et al.Vancomycinassociated nephrotoxicity:grave concern or death by character assassination?[J].Am J Med,2010,123(2):182.
10MEIER P,FROIDEVAUX C,DAYER E,et al.Cystatin C concentration and glomerular filtration rate[J].Lancet,2001,357(9256):634-635.
